A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreas cancer
B. A. Brown, P. J. Myers, S. J. Adair, J. R. Pitarresi, S. K. Sah-Teli, L. A. Campbell, W. S. Hart, M. Barbeau, K. Leong, N. Seyler, W. Kane, K. E. Lee, E. Stelow, M. Jones, M. C. Simon, P. Koivunen, T. W. Bauer, B. Z. Stanger, M. J. Lazzara
Abstract
Here, we show that hypoxia drives especially long-lasting epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) primarily through a positive-feedback histone methylation-MAPK signaling axis. We find that transformed cells preferentially undergo EMT in hypoxic tumor regions in multiple model systems and that hypoxia drives a cell-autonomous EMT in PDAC cells which, unlike EMT in response to growth factors, can last for weeks. We further demonstrate that hypoxia reduces histone demethylase KDM2A activity, suppresses PP2 family phosphatase expression, and activates MAPKs to post-translationally stabilize histone methyltransferase NSD2, leading to an H3K36me2-dependent EMT in which hypoxia-inducible factors play only a supporting role. This mechanism can be antagonized in vivo by combinations of MAPK inhibitors that may be effective in multi-drug therapies designed to target EMT.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hypoxia-induced histone methylation and NF-κB activation in pancreas cancer fibroblasts promote EMT-supportive growth factor secretion
Karl M. Kowalewski, Sara J. Adair, … Matthew J. Lazzara·bioRxiv·Jan 30, 2025
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer
Pradeep Moon Gunasekaran, Qianqian Wang, … Shin‐Heng Chiou·Nature CommunicationsPeer-reviewed·Jul 30, 2026
- Single-cell RNA sequencing reveals microenvironment context-specific routes for epithelial-mesenchymal transition in pancreas cancer cells
B. A. Brown, M. Lazzara·bioRxiv·May 30, 2023
- Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression
G. Liang, T. G. Oh, … R. M. Evans·Nature CommunicationsPeer-reviewed·Dec 6, 2023
- Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma
Maryam Safari, Luigi Scotto, … Susan Elaine Bates·Drug Resistance UpdatesPeer-reviewed·Oct 5, 2025
- Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer
A. Curiel-Garcia, S. Holmstrom, … K. P. Olive·bioRxiv·Mar 19, 2023